Semi-Annual Report — FY2026 H1
What CHUGAI PHARMACEUTICAL CO.,LTD. reported for the period from 2026-01-01 to 2026-06-30.
Filed 2026-07-27View the original on EDINET
How much it says
59Typical
What moved here
12named for the first time
Its own wording
15terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
For the first half of 2026 (1 January to 30 June 2026), revenue increased 14.7% year on year to ¥663.3 billion, operating profit increased 16.9% to ¥319.6 billion and interim profit increased 19.2% to ¥231.7 billion. In addition, an interim dividend of ¥66 per share, totalling ¥108,620 million, was approved with 30 June 2026 as the record date, and payments are scheduled to begin on 28 August 2026.
Komori's summary of this document, not the document's own words.59Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
68
Detailed
82
Very detailed
75
Very detailed
40
Thin
12
Almost nothing
37
Thin
62
Detailed
60
Detailed
55
Typical
73
Detailed
R&D spend902億円Money spent making new things.
Cash left over23億円Cash from the business, less what went into equipment.
Spent on equipment212億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.